1. Association of achieved blood pressure after treatment for primary aldosteronism with long-term kidney function
- Author
-
Tatsuya Haze, Yuichiro Yano, Yuichiro Yoshikawa, Tatsuya Kai, Takuyuki Katabami, Norio Wada, Yoshiro Chiba, Hiroki Kobayashi, Shoichiro Izawa, Yu Hatano, Mika Tsuiki, Jpas, Kouichi Tamura, Shintaro Okamura, Akiyo Tanabe, Takamasa Ichijo, Mitsuhide Naruse, Isao Kurihara, Masanobu Yamada, and Koichi Yamamoto
- Subjects
medicine.medical_specialty ,Kidney ,business.industry ,Hazard ratio ,Urology ,Renal function ,medicine.disease ,Confidence interval ,Primary aldosteronism ,medicine.anatomical_structure ,Blood pressure ,Cohort ,Internal Medicine ,medicine ,business ,Kidney disease - Abstract
Little is known regarding the association of blood pressure (BP) after treatment for primary aldosteronism (PA) (i.e., adrenalectomy and mineralocorticoid receptor antagonists) with long-term renal outcomes, and whether the association is independent of BP before treatment. Using a dataset from a nationwide registry of PA in Japan, we assessed whether achieved BP levels 6 months after treatment for PA are associated with annual changes in estimated glomerular filtration rate (eGFR), rapid eGFR decline, and incident chronic kidney disease (CKD) during the 5-year follow-up period. The cohort included 1266 PA patients. In multivariable linear regression including systolic BP (SBP) levels before treatment for PA, estimates (95% confidence interval [CI]) for annual changes in eGFR after month 6 associated with one-standard deviation (1-SD) higher SBP at month 6 were –0.08 (–0.15, –0.02) mL/min/1.73 m2/year. After multivariable adjustment, the estimate (95% CI) for annual changes in eGFR after month 6 was –0.12 (–0.21, –0.02) for SBP ≥ 130 mmHg vs. SBP
- Published
- 2021
- Full Text
- View/download PDF